Androgens and breast cancer

Steroids

Volumn 77, Issue 1-2, 2012, Pages 1-9

  Kotsopoulos, Joanne ^a,b   Narod, Steven A ^a,b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Androgens; Breast cancer; Testosterone

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; TESTOSTERONE DERIVATIVE;

ANDROGEN BLOOD LEVEL; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RISK; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; MENOPAUSAL SYNDROME; PROTEIN EXPRESSION; REVIEW;

ADULT; ANDROGENS; BRCA1 PROTEIN; BREAST; BREAST NEOPLASMS; EPIDEMIOLOGIC STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTMENOPAUSE; RECEPTORS, ANDROGEN; TESTOSTERONE;

EID: 83655167086     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.10.002     Document Type: Review

References (143)

1. B.E. Henderson, and H.S. Feigelson Hormonal carcinogenesis Carcinogenesis 21 3 2000 427 433 (Pubitemid 30137927)
2. J. Russo, and I.H. Russo The role of estrogen in the initiation of breast cancer J Steroid Biochem Mol Biol 102 1-5 2006 89 96 (Pubitemid 44750629)
3. A.H. Eliassen, and S.E. Hankinson Endogenous hormone levels and risk of breast, endometrial and ovarian cancer: prospective studies R.J. Berstein, Innovative endocrinology of cancer 2007 Landes Bioscience New York 148 165
4. C. Dimitrakakis, and C. Bondy Androgens and the breast Breast Cancer Res 11 5 2009 212
5. J.L. Shifren Transdermal testosterone treatment in women with impaired sexual function after oophorectomy N Engl J Med 343 10 2000 682 688
6. U.D. Rohr The impact of testosterone imbalance on depression and women's health Maturitas 41 Suppl. 1 2002 S25 S46
7. S.R. Davis Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality Maturitas 21 3 1995 227 236
8. R.M. Tamimi Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women Arch Intern Med 166 14 2006 1483 1489 (Pubitemid 44125867)
9. R.B. Ness Influence of estrogen plus testosterone supplementation on breast cancer Arch Intern Med 169 1 2009 41 46
10. H.G. Burger Androgen production in women Fertil Steril 77 Suppl. 4 2002 S3 S5
11. A. Endoh The zona reticularis is the site of biosynthesis of dehydroepiandrosterone and dehydroepiandrosterone sulfate in the adult human adrenal cortex resulting from its low expression of 3 beta-hydroxysteroid dehydrogenase J Clin Endocrinol Metab 81 10 1996 3558 3565 (Pubitemid 26339915)
12. C. Longcope Adrenal and gonadal androgen secretion in normal females Clin Endocrinol Metab 15 2 1986 213 228 (Pubitemid 16001793)
13. E. Knochenhauer, and R. Azziz Ovarian hormones and adrenal androgens during a woman's life span J Am Acad Dermatol 45 Suppl. 3 2001 S105 S115
14. L.R. Nelson, and S.E. Bulun Estrogen production and action J Am Acad Dermatol 45 Suppl. 3 2001 S116 S124
15. H.G. Burger The endocrinology of the menopause Maturitas 23 2 1996 129 136 (Pubitemid 126351815)
16. H.L. Judd Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood J Clin Endocrinol Metab 39 6 1974 1020 1024
17. E.Y. Adashi The climacteric ovary as a functional gonadotropin-driven androgen-producing gland Fertil Steril 62 1 1994 20 27 (Pubitemid 24198053)
18. H.L. Judd Hormonal dynamics associated with the menopause Clin Obstet Gynecol 19 4 1976 775 788 (Pubitemid 8007370)
19. B. Zumoff Sex differences in the twenty-four-hour mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate (DHAS) and the DHA to DHAS ratio in normal adults J Clin Endocrinol Metab 51 2 1980 330 333 (Pubitemid 10007644)
20. R.A. Lobo Androgens in postmenopausal women: production, possible role, and replacement options Obstet Gynecol Surv 56 6 2001 361 376 (Pubitemid 32520648)
21. T.M. Penning Molecular endocrinology of hydroxysteroid dehydrogenases Endocr Rev 18 3 1997 281 305 (Pubitemid 27246879)
22. H.D. Nelson Menopause Lancet 371 9614 2008 760 770 (Pubitemid 351288876)
23. B.E. Henderson Do regular ovulatory cycles increase breast cancer risk? Cancer 56 5 1985 1206 1208 (Pubitemid 15003511)
24. L. Bernstein Epidemiology of endocrine-related risk factors for breast cancer J Mammary Gland Biol Neoplasia 7 1 2002 3 15 (Pubitemid 38420778)
25. G.A. Colditz Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer J Natl Cancer Inst 90 11 1998 814 823 (Pubitemid 28280547)
26. C.L. Shufelt, and G.D. Braunstein Testosterone and the breast Menopause Int 14 3 2008 117 122
27. D.J. Liao, and R.B. Dickson Roles of androgens in the development, growth, and carcinogenesis of the mammary gland J Steroid Biochem Mol Biol 80 2 2002 175 189 (Pubitemid 34233739)
28. R. Grattarola The premenstrual endometrial pattern of women with breast cancer. A study of progestational activity Cancer 17 1964 1119 1122
29. R. Grattarola Androgens in breast cancer. I. Atypical endometrial hyperplasia and breast cancer in married premenopausal women Am J Obstet Gynecol 116 3 1973 423 428
30. R. Grattarola Urinary excretion of 11-deoxy-17-ketosteroids by patients with breast cancer with or without ovulatory cycles J Endocrinol 38 1 1967 77 78
31. R. Grattarola Increased androgenic activity in the etiology of cancer of the breast Cancro 23 3 1970 147 151
32. G. Secreto Androgens and Breast Cancer. The hyperandrogenic theory of breast cancer: past, present and future L. Ardis, Testosterone research trends 2007 Nova Science Publishers, Inc. New York 105 138
33. G. Secreto Testosterone and biological characteristics of breast cancers in postmenopausal women Cancer Epidemiol Biomarkers Prev 18 11 2009 2942 2948
34. C. Dimitrakakis, J. Zhou, and C.A. Bondy Androgens and mammary growth and neoplasia Fertil Steril 77 Suppl. 4 2002 S26 S33
35. B. Xie, S.W. Tsao, and Y.C. Wong Induction of high incidence of mammary tumour in female noble rats with a combination of 17beta-oestradiol and testosterone Carcinogenesis 20 6 1999 1069 1078 (Pubitemid 29263753)
36. A. Gadducci Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol 20 4 2005 200 208 (Pubitemid 40862906)
37. J. Zhou Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression FASEB J 14 12 2000 1725 1730
38. W. Somboonporn, and S.R. Davis Testosterone effects on the breast: implications for testosterone therapy for women Endocr Rev 25 3 2004 374 388 (Pubitemid 38780666)
39. F. Labrie Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone Endocr Rev 24 2 2003 152 182 (Pubitemid 36515283)
40. C. Dimitrakakis Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy Menopause 11 5 2004 531 535 (Pubitemid 40362151)
41. C. Dimitrakakis A physiologic role for testosterone in limiting estrogenic stimulation of the breast Menopause 10 4 2003 292 298 (Pubitemid 36870501)
42. R. Kaaks Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition Endocr Relat Cancer 12 4 2005 1071 1082 (Pubitemid 41815798)
43. S.A. Missmer Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women J Natl Cancer Inst 96 24 2004 1856 1865 (Pubitemid 40081323)
44. T. Key Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies J Natl Cancer Inst 94 8 2002 606 616 (Pubitemid 34498648)
45. J. Manjer Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden) Cancer Causes Control 14 7 2003 599 607 (Pubitemid 37211116)
46. C.G. Woolcott Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the multiethnic Cohort study Endocr Relat Cancer 17 1 2010 125 134
47. L. Baglietto Circulating steroid hormone levels and risk of breast cancer for postmenopausal women Cancer Epidemiol Biomarkers Prev 19 2 2010 492 502
48. A. Zeleniuch-Jacquotte Endogenous estrogens and risk of breast cancer by estrogen receptor status: a prospective study in postmenopausal women Cancer Epidemiol Biomarkers Prev 4 8 1995 857 860
49. S. Sieri Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort Cancer Epidemiol Biomarkers Prev 18 1 2009 169 176
50. D.K. Wysowski Sex hormone levels in serum in relation to the development of breast cancer Am J Epidemiol 125 5 1987 791 799 (Pubitemid 17066478)
51. H.V. Thomas A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey Br J Cancer 75 7 1997 1075 1079 (Pubitemid 27122629)
52. A. Micheli Endogenous sex hormones and subsequent breast cancer in premenopausal women Int J Cancer 112 2 2004 312 318 (Pubitemid 39244371)
53. R. Kaaks Serum sex steroids in premenopausal women and breast cancer risk within the European prospective investigation into cancer and nutrition (EPIC) J Natl Cancer Inst 97 10 2005 755 765 (Pubitemid 40879595)
54. J.F. Dorgan Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk Breast Cancer Res 12 6 2010 R98
55. A.H. Eliassen Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women J Natl Cancer Inst 98 19 2006 1406 1415 (Pubitemid 44530717)
56. J.W. Byng The quantitative analysis of mammographic densities Phys Med Biol 39 10 1994 1629 1638 (Pubitemid 24306719)
57. C. Byrne Mammographic features and breast cancer risk: effects with time, age, and menopause status J Natl Cancer Inst 87 21 1995 1622 1629
58. N.F. Boyd Mammographic density and the risk and detection of breast cancer N Engl J Med 356 3 2007 227 236 (Pubitemid 46143226)
59. K. Kerlikowske The mammogram that cried Wolfe N Engl J Med 356 3 2007 297 300 (Pubitemid 46143234)
60. V.A. McCormack, and I. dos Santos Silva Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis Cancer Epidemiol Biomarkers Prev 15 6 2006 1159 1169
61. M. Clemons, and P. Goss Estrogen and the risk of breast cancer N Engl J Med 344 4 2001 276 285 (Pubitemid 32108534)
62. N.F. Boyd Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention Curr Oncol Rep 3 4 2001 314 321
63. M. Yaffe Is mammographic density, as currently measured, a robust surrogate marker for breast cancer? Gynecol Endocrinol 21 Suppl. 1 2005 17 21 (Pubitemid 41345496)
64. L.J. Martin, and N.F. Boyd Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence Breast Cancer Res 10 1 2008 201
65. N.F. Boyd The association of breast mitogens with mammographic densities Br J Cancer 87 8 2002 876 882 (Pubitemid 35252963)
66. J.J. Noh Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women Breast 15 1 2006 20 28 (Pubitemid 43210545)
67. K. Walker Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors Cancer Res 69 16 2009 6490 6499
68. R. Warren Hormones and mammographic breast density Maturitas 49 1 2004 67 78 (Pubitemid 39209373)
69. J. Brisson Tamoxifen and mammographic breast densities Cancer Epidemiol Biomarkers Prev 9 9 2000 911 915
70. J. Cuzick Tamoxifen and breast density in women at increased risk of breast cancer J Natl Cancer Inst 96 8 2004 621 628 (Pubitemid 38584986)
71. R.M. Tamimi Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women J Natl Cancer Inst 99 15 2007 1178 1187 (Pubitemid 47233068)
72. M. Hofling Testosterone addition during menopausal hormone therapy: effects on mammographic breast density Climacteric 10 2 2007 155 163 (Pubitemid 46482169)
73. S.R. Davis The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy J Clin Endocrinol Metab 94 12 2009 4907 4913
74. A.O. Brinkmann The human androgen receptor: domain structure, genomic organization and regulation of expression J Steroid Biochem 34 1-6 1989 307 310 (Pubitemid 20061799)
75. R.M. Evans The steroid and thyroid hormone receptor superfamily Science 240 4854 1988 889 895
76. B. Nicolas Diaz-Chico Androgens and androgen receptors in breast cancer J Steroid Biochem Mol Biol 105 1-5 2007 1 15 (Pubitemid 47214620)
77. G.S. Prins Molecular biology of the androgen receptor Mayo Clin Proc 75 Suppl. 2000 S32 S35
78. R. Hu Androgen receptor expression and breast cancer survival in postmenopausal women Clin Cancer Res 17 7 2011 1867 1874
79. L.O. Gonzalez Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast Histopathology 50 7 2007 866 874 (Pubitemid 46850062)
80. W. Schippinger Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer Virchows Arch 449 1 2006 24 30 (Pubitemid 43988362)
81. J. Zhou Primate mammary gland insulin-like growth factor system: cellular localization and regulation by sex steroids J Invest Med 49 1 2001 47 55 (Pubitemid 32112583)
82. F. Moinfar Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies Cancer 98 4 2003 703 711 (Pubitemid 36959265)
83. Y. Ogawa Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers Int J Clin Oncol 13 5 2008 431 435
84. J.P. Persijn, C.B. Korsten, and E. Engelsman Oestrogen and androgen receptors in breast cancer and response to endocrine therapy Br Med J 4 5995 1975 503
85. L.O. Gonzalez Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors BMC Cancer 8 2008 149
86. A.A. Peters Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer Cancer Res 69 15 2009 6131 6140
87. H. Soiland Prognostic relevance of androgen receptor detection in operable breast cancer J Surg Oncol 98 7 2008 551 558
88. I. Castellano Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers Breast Cancer Res Treat 124 3 2010 607 617
89. R.M. Bryan Androgen receptors in breast cancer Cancer 54 11 1984 2436 2440 (Pubitemid 15223385)
90. S. Park Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers Ann Oncol 22 8 2011 1755 1762
91. S.N. Agoff Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations Am J Clin Pathol 120 5 2003 725 731 (Pubitemid 37339680)
92. S. Park Expression of androgen receptors in primary breast cancer Ann Oncol 21 3 2010 488 492
93. A. Gucalp, and T.A. Traina Triple-negative breast cancer: role of the androgen receptor Cancer J 16 1 2010 62 65
94. E.A. Rakha Prognostic markers in triple-negative breast cancer Cancer 109 1 2007 25 32 (Pubitemid 46120191)
95. X. Luo Expression and clinical significance of androgen receptor in triple negative breast cancer Chin J Cancer 29 6 2010 585 590
96. A.M. Gonzalez-Angulo Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer Clin Cancer Res 15 7 2009 2472 2478
97. P. Iversen Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup J Urol 164 5 2000 1579 1582
98. N.L. Chamberlain, E.D. Driver, and R.L. Miesfeld The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function Nucleic Acids Res 22 15 1994 3181 3186 (Pubitemid 24260654)
99. Y. Hao Association between androgen receptor gene CAG repeat polymorphism and breast cancer risk: a meta-analysis Breast Cancer Res Treat 124 3 2010 815 820
100. T.R. Rebbeck Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat Am J Hum Genet 64 5 1999 1371 1377 (Pubitemid 30468755)
101. C. Menin Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer Cancer Lett 168 1 2001 31 36 (Pubitemid 32463909)
102. E. Dagan Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype Eur J Hum Genet 10 11 2002 724 728 (Pubitemid 35460581)
103. C.A. Haiman The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study Cancer Res 62 4 2002 1045 1049 (Pubitemid 34160285)
104. E. Giovannucci The CAG repeat within the androgen receptor gene and its relationship to prostate cancer Proc Natl Acad Sci USA 94 7 1997 3320 3323 (Pubitemid 27157309)
105. S.A. Ingles Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor J Natl Cancer Inst 89 2 1997 166 170 (Pubitemid 27034793)
106. J.L. Stanford Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk Cancer Res 57 6 1997 1194 1198 (Pubitemid 27138622)
107. D. Ding Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action Prostate 62 2 2005 133 139 (Pubitemid 40096779)
108. A.M. Dunning No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer Carcinogenesis 20 11 1999 2131 2135 (Pubitemid 29535315)
109. L. Kadouri CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers Br J Cancer 85 1 2001 36 40 (Pubitemid 32695713)
110. N.M. Suter Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women Cancer Epidemiol Biomarkers Prev 12 2 2003 127 135 (Pubitemid 36194002)
111. B.L. Chang Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk Hum Genet 110 2 2002 122 129
112. L. Westberg Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women J Clin Endocrinol Metab 86 6 2001 2562 2568 (Pubitemid 32545707)
113. I.S. Brum Association between androgen receptor gene CAG repeat polymorphism and plasma testosterone levels in postmenopausal women J Soc Gynecol Invest 12 2 2005 135 141 (Pubitemid 40202850)
114. L. Ibanez Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism J Clin Endocrinol Metab 88 7 2003 3333 3338 (Pubitemid 36877513)
115. M. Hietala Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women Hum Reprod 22 1 2007 83 91 (Pubitemid 44942669)
116. F. Al-Azzawi, and S. Palacios Hormonal changes during menopause Maturitas 63 2 2009 135 137
117. B.B. Sherwin Changes in sexual behavior as a function of plasma sex steroid levels in post-menopausal women Maturitas 7 3 1985 225 233 (Pubitemid 16229789)
118. B.B. Sherwin, and M.M. Gelfand The role of androgen in the maintenance of sexual functioning in oophorectomized women Psychosom Med 49 4 1987 397 409 (Pubitemid 17138572)
119. G.D. Braunstein Androgen insufficiency in women: summary of critical issues Fertil Steril 77 Suppl. 4 2002 S94 S99
120. M.C. Padero, S. Bhasin, and T.C. Friedman Androgen supplementation in older women: too much hype, not enough data J Am Geriatr Soc 50 6 2002 1131 1140 (Pubitemid 34666324)
121. J.E. Rossouw Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial JAMA 288 3 2002 321 333 (Pubitemid 34761611)
122. V. Beral Breast cancer and hormone-replacement therapy in the million women study Lancet 362 9382 2003 419 427 (Pubitemid 36999703)
123. S.A. Narod Hormone replacement therapy and the risk of breast cancer Nat Rev Clin Oncol 2011 [Epub ahead of print]
124. M. Ewertz Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark Int J Cancer 42 6 1988 832 838 (Pubitemid 19012909)
125. S.S. Jick Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer Obstet Gynecol 113 1 2009 74 80
126. S.R. Davis The incidence of invasive breast cancer among women prescribed testosterone for low libido J Sex Med 6 7 2009 1850 1856
127. G. Mor 17Alpha-methyl testosterone is a competitive inhibitor of aromatase activity in Jar choriocarcinoma cells and macrophage-like THP-1 cells in culture J Steroid Biochem Mol Biol 79 1-5 2001 239 246 (Pubitemid 34158800)
128. M. Hofling Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women Menopause 14 2 2007 183 190 (Pubitemid 46673468)
129. M.S. Beattie Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP breast cancer prevention trial (P-1) J Natl Cancer Inst 98 2 2006 110 115 (Pubitemid 43159965)
130. A. Eisen Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study J Clin Oncol 23 30 2005 7491 7496 (Pubitemid 46291812)
131. T.R. Rebbeck, N.D. Kauff, and S.M. Domchek Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers J Natl Cancer Inst 101 2 2009 80 87
132. A. Finch Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation JAMA 296 2 2006 185 192
133. A. Eisen Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers J Natl Cancer Inst 100 19 2008 1361 1367
134. T.R. Rebbeck Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group J Clin Oncol 23 31 2005 7804 7810 (Pubitemid 46657377)
135. A. Finch The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation Gynecol Oncol 121 1 2011 163 168
136. A.L. Chand, E.R. Simpson, and C.D. Clyne Aromatase expression is increased in BRCA1 mutation carriers BMC Cancer 9 2009 148
137. G. Pristauz Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations Histopathology 57 6 2010 877 884
138. E.M. Berns Androgen pathway dysregulation in BRCA1-mutated breast tumors Breast Cancer Res Treat 79 1 2003 121 127 (Pubitemid 36561049)
139. J.J. Park Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor Cancer Res 60 21 2000 5946 5949
140. S. Fan Role of direct interaction in BRCA1 inhibition of estrogen receptor activity Oncogene 20 1 2001 77 87 (Pubitemid 32142340)
141. R. Hackenberg, and K.D. Schulz Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids J Steroid Biochem Mol Biol 56 1-6 1996 113 117 [Spec No.] (Pubitemid 26107886)
142. J. Szelei Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor Endocrinology 138 4 1997 1406 1412 (Pubitemid 27137086)
143. I.S. Goldenberg Combined androgen and antimetabolite therapy of advanced female breast cancer. A report of the cooperative breast cancer group Cancer 36 2 1975 308 310